High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial

Anneke C. Hesseling; S. Kim; S. Madhi; S. Nachman; H. S. Schaaf; A. Violari; T. C. Victor; G. McSherry; C. Mitchell; M. F. Cotton

doi:10.5588/ijtld.10.0795

High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial

Anneke C. Hesseling, S. Kim, S. Madhi, S. Nachman, H. S. Schaaf, A. Violari, T. C. Victor, G. McSherry, C. Mitchell, M. F. Cotton

Pediatrics

Research output: Contribution to journal › Article

10 Scopus citations

Abstract

An emergence of drug-resistant tuberculosis (DR-TB) in settings affected by human immunodeficiency virus (HIV) and tuberculosis (TB) has been observed. We investigated the prevalence of DR-TB in P1041, a multicentred, randomised, double-blind trial which compared the administration of isoniazid (INH) to placebo, in HIV-exposed, non-infected and -infected African infants in the absence of any documented TB exposure. The prevalence of multidrug-resistant TB (MDR-TB) was 22.2% (95%CI 8.5-45.8) and INH monoresistance 5.6% (95%CI 0.1-27.6) among culture-confirmed cases, with all MDR-TB occurring in a single site. There was no association between INH treatment or placebo group, or between HIV infection status, and DR-TB prevalence. There was a high prevalence of DR-TB among HIV-exposed and -infected children. Surveillance of DR-TB among children in high-burden TB-HIV settings should be routine.

Original language	English (US)
Pages (from-to)	192-195
Number of pages	4
Journal	International Journal of Tuberculosis and Lung Disease
Volume	16
Issue number	2
DOIs	https://doi.org/10.5588/ijtld.10.0795
State	Published - Feb 1 2012

Keywords

Children
HIV
Isoniazid prevention
Resistance
Tuberculosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Infectious Diseases

Access to Document

10.5588/ijtld.10.0795

Fingerprint Dive into the research topics of 'High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial'. Together they form a unique fingerprint.

Cite this

Hesseling, A. C., Kim, S., Madhi, S., Nachman, S., Schaaf, H. S., Violari, A., Victor, T. C., McSherry, G., Mitchell, C., & Cotton, M. F. (2012). High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial. International Journal of Tuberculosis and Lung Disease, 16(2), 192-195. https://doi.org/10.5588/ijtld.10.0795

High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial. / Hesseling, Anneke C.; Kim, S.; Madhi, S.; Nachman, S.; Schaaf, H. S.; Violari, A.; Victor, T. C.; McSherry, G.; Mitchell, C.; Cotton, M. F.

In: International Journal of Tuberculosis and Lung Disease, Vol. 16, No. 2, 01.02.2012, p. 192-195.

Research output: Contribution to journal › Article

@article{ed9e4c5ec23b4f3e8cc0d05143e19f78,

title = "High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial",

abstract = "An emergence of drug-resistant tuberculosis (DR-TB) in settings affected by human immunodeficiency virus (HIV) and tuberculosis (TB) has been observed. We investigated the prevalence of DR-TB in P1041, a multicentred, randomised, double-blind trial which compared the administration of isoniazid (INH) to placebo, in HIV-exposed, non-infected and -infected African infants in the absence of any documented TB exposure. The prevalence of multidrug-resistant TB (MDR-TB) was 22.2% (95%CI 8.5-45.8) and INH monoresistance 5.6% (95%CI 0.1-27.6) among culture-confirmed cases, with all MDR-TB occurring in a single site. There was no association between INH treatment or placebo group, or between HIV infection status, and DR-TB prevalence. There was a high prevalence of DR-TB among HIV-exposed and -infected children. Surveillance of DR-TB among children in high-burden TB-HIV settings should be routine.",

keywords = "Children, HIV, Isoniazid prevention, Resistance, Tuberculosis",

author = "Hesseling, {Anneke C.} and S. Kim and S. Madhi and S. Nachman and Schaaf, {H. S.} and A. Violari and Victor, {T. C.} and G. McSherry and C. Mitchell and Cotton, {M. F.}",

year = "2012",

month = feb,

day = "1",

doi = "10.5588/ijtld.10.0795",

language = "English (US)",

volume = "16",

pages = "192--195",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "2",

}

TY - JOUR

T1 - High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial

AU - Hesseling, Anneke C.

AU - Kim, S.

AU - Madhi, S.

AU - Nachman, S.

AU - Schaaf, H. S.

AU - Violari, A.

AU - Victor, T. C.

AU - McSherry, G.

AU - Mitchell, C.

AU - Cotton, M. F.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - An emergence of drug-resistant tuberculosis (DR-TB) in settings affected by human immunodeficiency virus (HIV) and tuberculosis (TB) has been observed. We investigated the prevalence of DR-TB in P1041, a multicentred, randomised, double-blind trial which compared the administration of isoniazid (INH) to placebo, in HIV-exposed, non-infected and -infected African infants in the absence of any documented TB exposure. The prevalence of multidrug-resistant TB (MDR-TB) was 22.2% (95%CI 8.5-45.8) and INH monoresistance 5.6% (95%CI 0.1-27.6) among culture-confirmed cases, with all MDR-TB occurring in a single site. There was no association between INH treatment or placebo group, or between HIV infection status, and DR-TB prevalence. There was a high prevalence of DR-TB among HIV-exposed and -infected children. Surveillance of DR-TB among children in high-burden TB-HIV settings should be routine.

AB - An emergence of drug-resistant tuberculosis (DR-TB) in settings affected by human immunodeficiency virus (HIV) and tuberculosis (TB) has been observed. We investigated the prevalence of DR-TB in P1041, a multicentred, randomised, double-blind trial which compared the administration of isoniazid (INH) to placebo, in HIV-exposed, non-infected and -infected African infants in the absence of any documented TB exposure. The prevalence of multidrug-resistant TB (MDR-TB) was 22.2% (95%CI 8.5-45.8) and INH monoresistance 5.6% (95%CI 0.1-27.6) among culture-confirmed cases, with all MDR-TB occurring in a single site. There was no association between INH treatment or placebo group, or between HIV infection status, and DR-TB prevalence. There was a high prevalence of DR-TB among HIV-exposed and -infected children. Surveillance of DR-TB among children in high-burden TB-HIV settings should be routine.

KW - Children

KW - HIV

KW - Isoniazid prevention

KW - Resistance

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84862934325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862934325&partnerID=8YFLogxK

U2 - 10.5588/ijtld.10.0795

DO - 10.5588/ijtld.10.0795

M3 - Article

C2 - 22236919

AN - SCOPUS:84862934325

VL - 16

SP - 192

EP - 195

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 2

ER -